Ng Shu Y, Colborn Kathryn L, Cambridge Lajhem, Hajj Carla, Yang T Jonathan, Wu Abraham J, Goodman Karyn A
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Division of Health Care Policy and Research, Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Denver School of Medicine, USA.
Radiother Oncol. 2016 Nov;121(2):252-257. doi: 10.1016/j.radonc.2016.09.010. Epub 2016 Oct 14.
We examined acute toxicity profiles and outcomes among rectal cancer patients treated with pre-operative chemoradiation using intensity modulated radiotherapy (IMRT) or 3-dimensional conformal radiotherapy (3DCRT) to identify predictive clinical factors associated with increased acute toxicity.
We retrospectively reviewed records of 301 consecutive rectal cancer patients treated with pre-operative chemotherapy and radiotherapy (median dose 5000cGy) at our institution between 2007 and 2014.
Of the 301 patients, 203 (67.4%) were treated with IMRT and 98 (32.6%) with 3DCRT. Significantly more patients experienced ⩾grade 2 diarrhea in the 3DCRT group compared to the IMRT group (22% vs 10%, p=0.004), and those who received 3DCRT had 2.7 times greater odds of a higher diarrhea score than those on IMRT, even after adjusting for patient characteristics and chemotherapy (OR 2.71, p=0.01) Fewer patients experienced grade 2 genitourinary toxicity in the IMRT group (6% vs 13% 3DCRT, p=0.04) and there was a trend toward decreased grade 2 proctitis in the IMRT group (22% vs 32% 3DCRT, p=0.07). Patients over the age of 55 had 45% lower odds of proctitis than patients younger than 55.
The use of IMRT significantly reduced grade ⩾2 diarrhea and GU toxicity during chemoradiation. Younger patients were more likely to report grade 2 or higher proctitis.
我们研究了采用调强放疗(IMRT)或三维适形放疗(3DCRT)进行术前放化疗的直肠癌患者的急性毒性特征及结果,以确定与急性毒性增加相关的预测性临床因素。
我们回顾性分析了2007年至2014年间在我院接受术前化疗和放疗(中位剂量5000cGy)的301例连续直肠癌患者的记录。
301例患者中,203例(67.4%)接受IMRT治疗,98例(32.6%)接受3DCRT治疗。与IMRT组相比,3DCRT组中出现≥2级腹泻的患者明显更多(22%对10%,p = 0.004),即使在调整患者特征和化疗因素后,接受3DCRT治疗的患者出现更高腹泻评分的几率比接受IMRT治疗的患者高2.7倍(OR 2.71,p = 0.01)。IMRT组中出现2级泌尿生殖系统毒性的患者较少(6%对3DCRT组的13%,p = 0.04),并且IMRT组有2级直肠炎发生率降低的趋势(22%对3DCRT组的32%,p = 0.07)。55岁以上的患者发生直肠炎的几率比55岁以下的患者低45%。
IMRT的使用显著降低了放化疗期间≥2级腹泻和泌尿生殖系统毒性。年轻患者更有可能报告2级或更高等级的直肠炎。